ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...
Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...
This illustration shows targeted alpha therapy, in which actinium-225 is linked to a targeting molecule that binds to a cancer cell and delivers ...
Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market is in its ...
Osaka, Japan – For many years, radioactive iodine which emits beta rays has been used for treatment of thyroid cancer. Generally, 5-year survival rates may exceed 90%. However, some thyroid tumors ...
Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer. The first assessments - ...
In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent ...
Therapy options are limited for men with advanced-stage, metastatic castration-resistant prostate cancer, but a new treatment protocol offers hope. Researchers report on their novel dosing regimen for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results